Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection

Translational Oncology

Volumn 7, Issue 2, 2014, Pages 248-255

  Liao, Weijia ^a,b   Zhang, Jingmei ^c   Zhu, Qun ^d   Qin, Liling ^a,b   Yao, Wenmin ^a   Lei, Biao ^a   Shi, Wuxiang ^a   Yuan, Shengguang ^a,b   Tahir, Syed Abdul ^a   Jin, Junfei ^a,b   He, Songqing ^a,b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; SENSITIVITY AND SPECIFICITY; TUMOR THROMBUS; TUMOR VOLUME;

EID: 84902474493     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.02.011     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, and Wildman RP, et al (2005). Major causes of death among men and women in China. N Engl J Med 353, 1124-1134.
3. Poon RT (2011). Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology 54, 757-759.
4. Tralhão JG, Dagher I, Lino T, Roudié J, and Franco D (2007). Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol 33, 746-751.
5. Shimada K, Sano T, Sakamoto Y, and Kosuge T (2005). A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer 104, 1939-1947.
6. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, and Fukushima M (2007). The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73, 215-220.
7. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, and Kim YJ (2011). Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 104, 504-510.
8. Yao Y, Yuan D, Liu H, Gu X, and Song Y (2013). Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 62, 471-479.
9. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, and Carducci MA (2012). The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48, 202-208.
10. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, and Pummer K, et al (2013). Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108, 901-907.
11. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, and Widmann WD (2012). Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol 19, 217-224.
12. Chua W, Charles KA, Baracos VE, and Clarke SJ (2011). Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104, 1288-1295.
13. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, and Lackner C, et al (2013). Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109, 416-421.
14. Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, Glehr M, Zacherl M, Stojakovic T, and Gerger A, et al (2013). Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer 108, 1677-1683.
15. Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, and Lee S (2013). Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer 13, 78.
16. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, and Chen GH (2011). A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One 6, e25295.
17. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, and Prasad KR (2008). Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32, 1757-1762.
18. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, and Pinna AD (2011). Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 91, 1279-1285.
19. Grivennikov SI, Greten FR, and Karin M (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
20. McDonald B, Spicer J, Giannais B, Fallavollita L, Brodt P, and Ferri LE (2009). Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 125, 1298-1305.
21. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, and Clarke SJ (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16, 5805-5813.
22. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H, and Tajiri H (2012). Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer 107, 988-993.
23. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, and Gurm HS (2008). Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 102, 653-657.
24. Maxwell PJ, Coulter J, Walker SM, McKechnie M, Neisen J, McCabe N, Kennedy RD, Salto-Tellez M, Albanese C, and Waugh DJ (2013). Potentiation of Inflammatory CXCL8 Signalling Sustains Cell Survival in PTEN-deficient Prostate Carcinoma. Eur Urol 64, 177-188.
25. Sivaramakrishnan V and Niranjali Devaraj S (2009). Morin regulates the expression of NF-B-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma. Chem Biol Interact 180, 353-359.
26. Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, Wang J, Zhang D, Cheng S, and Liu S (2013). Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology 144, 1031-1041.
27. Halazun KJ, Hardy MA, Rana AA, Woodland 4th DC, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown Jr RS, and Emond JC (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 250, 141-151.
28. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, and Zheng L (2011). Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 54, 948-955.
29. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, and Kong LH, et al (2010). Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 25, 1427-1433.
30. Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, and Lee VK, et al (2010). Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 52, 370-379.
31. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, and Huo TI, et al (2010). A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 53, 108-117.
32. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, and Fujishima T, et al (2005). Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54, 419-425.
33. Kow AW, Kwon CH, Song S, Shin M, Kim JM, and Joh JW (2012). Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma: review of 1222 cases of hepatectomy in a tertiary institution. Ann Surg Oncol 19, 2246-2255.
34. Cha C, Fong Y, Jarnagin WR, Blumgart LH, and DeMatteo RP (2003). Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197, 753-758.
35. Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF, and Chen XP (2012). Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 19, 2515-2525.
36. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, and Matejka J, et al (2011). Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 34, 949-959.
37. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, and Abou-Alfa GK (2010). Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28, 2889-2895.
38. Chang ML, Lin SM, and Yeh CT (2011). HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer. PLoS One 6, e26323.
39. Llovet JM, Schwartz M, and Mazzaferro V (2005). Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25, 181-200.
40. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, and Lerner J, et al (2008). Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359, 1995-2004.
41. Nathan H, Schulick RD, Choti MA, and Pawlik TM (2009). Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249, 799-805.
42. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, and Shi M (2011). Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 18, 413-420.
43. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, and Cavallari A (2003). Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237, 536-543.
44. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, Zhang BX, He SQ, and Zhang WG (2006). Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 13, 940-946.
45. Wang T, Hu HS, Feng YX, Shi J, Li N, Guo WX, Xue J, Xie D, Liu SR, and Wu MC, et al (2010). Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer 102, 1618-1626.